These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 33059738)

  • 21. Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat.
    Consalvi S; Mozzetta C; Bettica P; Germani M; Fiorentini F; Del Bene F; Rocchetti M; Leoni F; Monzani V; Mascagni P; Puri PL; Saccone V
    Mol Med; 2013 May; 19(1):79-87. PubMed ID: 23552722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histological effects of givinostat in boys with Duchenne muscular dystrophy.
    Bettica P; Petrini S; D'Oria V; D'Amico A; Catteruccia M; Pane M; Sivo S; Magri F; Brajkovic S; Messina S; Vita GL; Gatti B; Moggio M; Puri PL; Rocchetti M; De Nicolao G; Vita G; Comi GP; Bertini E; Mercuri E
    Neuromuscul Disord; 2016 Oct; 26(10):643-649. PubMed ID: 27566866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening.
    Moorwood C; Lozynska O; Suri N; Napper AD; Diamond SL; Khurana TS
    PLoS One; 2011; 6(10):e26169. PubMed ID: 22028826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zebrafish based small molecule screens for novel DMD drugs.
    Kawahara G; Kunkel LM
    Drug Discov Today Technol; 2013; 10(1):e91-6. PubMed ID: 24050235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
    Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
    FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases.
    Consalvi S; Saccone V; Giordani L; Minetti G; Mozzetta C; Puri PL
    Mol Med; 2011; 17(5-6):457-65. PubMed ID: 21308150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Pronase versus Manual Dechorionation of Zebrafish Embryos for Small Molecule Treatments.
    Hasegawa EH; Farr GH; Maves L
    J Dev Biol; 2023 Mar; 11(2):. PubMed ID: 37092478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SU9516 Increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy.
    Sarathy A; Wuebbles RD; Fontelonga TM; Tarchione AR; Mathews Griner LA; Heredia DJ; Nunes AM; Duan S; Brewer PD; Van Ry T; Hennig GW; Gould TW; Dulcey AE; Wang A; Xu X; Chen CZ; Hu X; Zheng W; Southall N; Ferrer M; Marugan J; Burkin DJ
    Mol Ther; 2017 Jun; 25(6):1395-1407. PubMed ID: 28391962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dystrophic muscle improvement in zebrafish via increased heme oxygenase signaling.
    Kawahara G; Gasperini MJ; Myers JA; Widrick JJ; Eran A; Serafini PR; Alexander MS; Pletcher MT; Morris CA; Kunkel LM
    Hum Mol Genet; 2014 Apr; 23(7):1869-78. PubMed ID: 24234649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluoxetine prevents dystrophic changes in a zebrafish model of Duchenne muscular dystrophy.
    Waugh TA; Horstick E; Hur J; Jackson SW; Davidson AE; Li X; Dowling JJ
    Hum Mol Genet; 2014 Sep; 23(17):4651-62. PubMed ID: 24760771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of small molecule and genetic modulators of AON-induced dystrophin exon skipping by high-throughput screening.
    O'Leary DA; Sharif O; Anderson P; Tu B; Welch G; Zhou Y; Caldwell JS; Engels IH; Brinker A
    PLoS One; 2009 Dec; 4(12):e8348. PubMed ID: 20020055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibro-adipogenic progenitors in dystrophic muscles.
    Saccone V; Consalvi S; Giordani L; Mozzetta C; Barozzi I; Sandoná M; Ryan T; Rojas-Muñoz A; Madaro L; Fasanaro P; Borsellino G; De Bardi M; Frigè G; Termanini A; Sun X; Rossant J; Bruneau BG; Mercola M; Minucci S; Puri PL
    Genes Dev; 2014 Apr; 28(8):841-57. PubMed ID: 24682306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
    J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of
    Prykhozhij SV; Caceres L; Ban K; Cordeiro-Santanach A; Nagaraju K; Hoffman EP; Berman JN
    Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duchenne muscular dystrophy drug discovery - the application of utrophin promoter activation screening.
    Moorwood C; Khurana TS
    Expert Opin Drug Discov; 2013 May; 8(5):569-81. PubMed ID: 23473647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levels of α7 integrin and laminin-α2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy.
    Wuebbles RD; Sarathy A; Kornegay JN; Burkin DJ
    Dis Model Mech; 2013 Sep; 6(5):1175-84. PubMed ID: 23846963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Steroid Responsiveness in Duchenne Muscular Dystrophy - Predictive Value of Epigenetic Regulator Histone Deacetylase 2.
    Pradhan S; Das A; Singh H; Chaturvedi S; Singh K; Mishra R; Misra DP; Agarwal V
    Indian J Pediatr; 2020 Sep; 87(9):692-698. PubMed ID: 32314166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
    St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
    Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.
    Hafner P; Bonati U; Rubino D; Gocheva V; Zumbrunn T; Gueven N; Fischer D
    Trials; 2016 Aug; 17(1):389. PubMed ID: 27488051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.